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Huntington’s disease (HD) and eight additional inherited neurological disorders are caused by CAG triplet-repeat expansions leading to
expanded polyglutamine-sequences in their respective proteins. These triplet-CAG repeat disorders have in common the formation of
aberrant intraneuronal proteinaceous inclusions containing the expanded polyglutamine sequences. These aggregates have been postu-
lated to contribute to pathogenesis caused by conformational toxicity, sequestration of other polyglutamine-containing proteins, or by
interfering with certain enzymatic activities. Testing these hypotheses has been hampered by the difficulty to isolate these aggregates
frombrain.Herewe report that polyglutamine aggregates canbe isolated from thebrain of theTet/HD94 conditionalmousemodel ofHD,
by following a method based on high salt buffer homogenization, nonionic detergent extraction, and gradient fractionation. We then
verified that themethod can be successfully applied to postmortemHD brains. Immunoelectronmicroscopy, both in human andmouse
samples, revealed that the stable component of the inclusions are mutant huntingtin-containing and ubiquitin-containing fibrils.
Atomic-force microscopy revealed that these fibrils have a “beads on a string” morphology. Thus, they resemble the in vitro assembled
filaments made of recombinant mutant-huntingtin, as well as the A and -synuclein amyloid protofibrils. Finally, by shutting down
transgene expression in the Tet/HD94 conditionalmousemodel of HD,wewere able to demonstrate that these filaments, although stable
in vitro, are susceptible to revert in vivo, thus demonstrating that the previously reported reversal of ubiquitin-immunoreactive inclu-
sions does not simply reflect disassembling of the inclusions into their constituent fibrils and suggesting that any associated conforma-
tional or protein-sequestration toxicity is also likely to revert.
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Introduction
Huntington’s disease (HD) is an autosomal dominant neurode-
generative disorder caused by a CAG triplet-repeat expansion
coding for a poly-glutamine (polyQ) sequence in the N-terminal
region of the huntingtin (htt) protein (HDCRG, 1993). Patients
suffer from motor dysfunction, cognitive decline, and psycholog-
ical disturbances over 10 –15 years until death, caused by brain
atrophy mainly in striatum and cortex (Vonsattel and DiFiglia,
1998).
At least eight other autosomal dominant neurological diseases
are also caused by a polyQ expansion mutation in their respective
proteins. These CAG triplet-repeat disorders include spinal and
bulbar muscular atrophy, several forms of spinocerebellar ataxia,
and dentatorubral and pallidolusyan atrophy (Zoghbi and Orr,
2000). All these diseases share an interesting commonality; the
presence of intraneuronal aggregates containing the expanded
polyQ in the affected areas of the brain (Ross, 1997; Nakamura et
al., 2001).
Despite the presence of intraneuronal aggregates in all CAG
triplet-repeat disorders, the relevance of aggregate formation to
the etiology of HD is unclear. Aggregates have been implicated as
the trigger for neurodegeneration, because both aggregates and
pathogenicity are caused by the same polyQ length threshold
(Scherzinger et al., 1997). Furthermore, in a transgenic mouse
model, these aggregates precede the onset of symptoms (Davies et
al., 1997). Nevertheless, although some studies using transfected
cells support aggregate-induced toxicity (Waelter et al., 2001),
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others dissociate inclusion formation and cell death (Kim et al.,
1999; Martin-Aparicio et al., 2001), and even suggest that in-
tranuclear inclusions may reflect a protective mechanism against
soluble htt-induced toxicity (Saudou et al., 1998; Kopito, 2000).
Although the role of polyQ-containing aggregates in HD
pathogenesis is still a matter of debate, several mechanisms by
which aggregates could trigger toxicity have been postulated.
These include conformational toxicity, as it has been proposed
for other neurodegenerative diseases with intraneuronal aberrant
aggregates of amyloidogenic proteins like A in Alzheimer’s dis-
ease and -synuclein in Parkinson’s disease (Bucciantini et al.,
2002). Another proposed pathogenic mechanism is the seques-
tration of other proteins containing nonpathogenic PolyQ se-
quences like CBP (Nucifora et al., 2001) or htt transcribed from
the nonmutated allele (Zuccato et al., 2001). Finally, because in-
traneuronal aggregates are stained with anti-ubiquitin and anti-
proteasome antibodies, an impairment of the ubiquitin protea-
some system by the aggregates has been proposed as the
pathogenic mechanism. Interestingly, work on transfected cell
models support this hypothesis (Bence et al., 2001; Jana et al.,
2001), although no evidence has been found so far in tissue from
patients or mouse models (Diaz-Hernandez et al., 2003; Herna´n-
dez et al., 2004).
PolyQ aggregates have never been purified from the brain of
patients of any of the CAG triplet-repeat disorders or from the
brain of any of the many available mouse models (Rubinsztein,
2002). The ability to purify these aggregates from the brain of HD
patients or from animal models would, by allowing their bio-
chemical and ultrastructural characterization, offer key informa-
tion about the possible contribution of the aggregates to the
pathogenesis of HD and other CAG triplet-repeat disorders. Sim-
ilarly to what has been done with isolated proteinaceous deposits
from Alzheimer’s disease (Selkoe, 1991) and Parkinson’s disease
brains (Pollanen et al., 1993).
Here we report the purification of huntingtin aggregates from
the Tet/HD94 conditional mouse model of HD (Yamamoto et al.,
2000; Martin-Aparicio et al., 2001) and from postmortem HD
brains. Biochemical studies, together with immunoelectron mi-
croscopy and atomic-force microscopy ultrastructural analysis,
revealed that the stable components of HD inclusions are
amyloid-like huntingtin filaments. Finally, by shutting down
transgene expression in the Tet/HD94 mice, we were able to dem-
onstrate that these filaments, although stable in vitro, are suscep-
tible to revert in vivo.
Materials andMethods
Animals
Tet/HD94 mice were generated as previously described (Yamamoto et
al., 2000). Mice were bred at the Centro de Biologı´a Molecular “Severo
Ochoa” (Madrid, Spain). Four or five mice were housed per cage with
food and water available ad libitum. Mice were maintained in a
temperature-controlled environment on a 12 hr light/dark cycle with
light onset at 7:00 A.M.
Antibodies
The following antibodies were used: anti- N-terminal mutant huntingtin
CAG53b (amino acids 1–118 with a 51 polyQ stretch, a kind gift from Dr.
Wanker, Berlin, Germany), anti--tubulin (Sigma, St. Louis, MO), anti-
-galactosidase (Promega, Madison, WI), anti-ubiquitin (Dako, Carpin-
teria, CA), anti-poly-ubiquitin conjugates (FK-2; Affinity Bioreagents,
Golden, CO), anti-N-terminal htt (N-18; Santa Cruz Biotechnology, Santa
Cruz, CA), and anti-expanded polyQ (1C2; Chemicon, Temecula, CA).
Human samples
Brain specimens used in this study were removed at autopsy from three
HD (one woman aged 65 years and two men aged 71 and 68 years) and
three age-matched controls (one woman aged 80 years and two men aged
63 and 79 years) following the protocols of nervous tissue donation ap-
proved by the local Ethical Committees of the Barcelona and Bellvitge
brain banks. The postmortem delay in tissue processing was between 4
and 15 hr in both groups. The neuropathological examination in HD
cases revealed a diagnosis of HD grade 4 following the criteria of Vonsat-
tel et al. (1985), revised in Vonsattel and DiFiglia (1998).
Immunohistochemistry
Mouse brain. Mice were anesthetized with a xylazine– ketamine solution
and transcardially perfused with 4% paraformaldehyde (PFA) in Sorens-
en’s buffer for 10 min. Brains were postfixed in 4% PFA for 2 hr at 4°C
and cryoprotected in 30% sucrose solution. Thirty micrometer sagittal
sections were cut on a freezing microtome (Leica, Nussloch, Germany)
and collected in 0.1% azide–PBS solution. Next, brain sections were
pretreated for 1 hr with 1% BSA, 5% FBS, and 0.2% Triton X-100 and
then incubated with primary antibodies at the following dilutions: anti-
polyubiquitin FK2 (1:500) and anti-N-terminal htt CAG53b (1:5000).
Finally, brain sections were incubated in avidin– biotin complex using
the Elite Vectastain kit (Vector Laboratories, Burlingame, CA). Chromo-
gen reactions were performed with 0.05% diaminobenzidine (DAB;
Sigma) and 0.01% H2O2 for 10 min. Sections were coverslipped with
Fluorosave.
Human brain. Samples (2-mm-thick) of the frontal cortex and stria-
tum from control and HD subjects were fixed at the time of the autopsy
in 4% paraformaldehyde for 24 – 48 hr and then immersed in 30% buff-
ered sucrose for 48 hr. Once cryoprotected, the samples were frozen and
stored at 80°C until use. Then, 30 m sections were obtained with a
cryostat and processed for free-floating immunohistochemistry in the
same conditions as described for the mouse samples. The primary anti-
bodies assayed were used at the same concentration previously described
for mouse samples. Immunoreaction was visualized with 0.05% DAB
and 0.01% H2O2 (brown precipitate).
Tissue processing for electron microscopy
For electron microscopy, immunostained vibratome sections were pro-
cessed as previously described (Lucas et al., 2001). Briefly, the sections
were postfixed in 2% OsO4 for 1 hr, dehydrated, embedded in Araldite,
and flat-mounted in Formvar-coated slides, using plastic coverslips. Af-
ter polymerization, selected areas were photographed, trimmed, re-
embedded in Araldite, and resectioned at 1 m. These semithin sections
were rephotographed and resectioned in ultrathin sections. The ultrathin
sections were observed in a Jeol electron microscope, without heavy
metal staining to avoid artifactual precipitates.
Aggregate purification procedure
For the isolation of huntingtin- and ubiquitin-containing aggregates
from brain tissue, we used protocol similar to the one previously used to
isolate aberrant intraneuronal proteinaceous deposits from the brains of
Alzheimer’s disease (Greenberg and Davies, 1990) and Parkinson’s dis-
ease patients (Pollanen et al., 1992). Briefly, the entire forebrain of Tet/
HD94 mice or cortical dissects from HD grade 4 cases (1–2 gm) was
homogenized in 6 ml of cold buffer 1 (10 mM Tris, 1 mM EGTA, 0.8 M
NaCl, 10% sucrose, 0.1% Triton X-100, and protease inhibitors) (2 mM
PMSF, 10g/ml aprotinin, 10g/ml leupeptin, and 10g/ml pepstatin)
in a glass homogenizer. After centrifugation at 27,000 g for 20 min at
4°C, the supernatant S1 was saved, and pellet P1 was homogenized again
in buffer 1 and then was centrifuged at 27,000  g for 20 min. The
supernatants S1 and S2 were combined, adjusted to 1% (w/v)
N-lauroylsarcosine (Sarkosyl) and 1% (v/v) 2 mercaptoethanol, and in-
cubated at room temperature for 2 hr in agitation on an orbital shaker.
After centrifugation at 100,000 g for 45 min the huntingtin filaments
pellets were homogenized in 2 ml of buffer 3 (10 mM Tris, 1 mM EGTA,
0.8 M NaCl, 10% sucrose, and protease inhibitors) (2 mM PMSF, 10
g/ml aprotinin, 10 g/ml leupeptin, and 10 g/ml pepstatin) and lay-
ered over a discontinuous sucrose gradient consisting of 4 ml of 50%
sucrose and 4 ml of 20% sucrose in 10 mM Tris, 1 mM EGTA, 0.8 M NaCl.
After centrifugation for 2 hr at 150,000  g, the htt filaments were col-
lected from 20 –50% interface and were stored at 70°C until used for
further analysis.
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Western blot analysis
Mouse samples. Extracts for Western blot analysis were obtained from
different steps of Huntingtin filament-enriched fraction preparation and
treated with protease inhibitors (2 mM PMSF, 10 g/ml aprotinin, 10
g/ml leupeptin, and 10 g/ml pepstatin). The samples were homoge-
nized at 4°C, and protein content was determined by Bradford. Total
protein (20 g) was electrophoresed on 10% SDS-PAGE gel and trans-
ferred to a nitrocellulose membrane (Schleicher & Schuell, Dassell, Ger-
many). The experiments were performed using the following primary
antibodies: polyclonal anti-polyglutamine expansion 1C2 (1:500),
monoclonal anti-poly-ubiquitin FK2 clone (1:2000), polyclonal anti-
huntingtin N-terminal CAG53b (1:5000), polyclonal anti-ubiquitin (1:
1000), and polyclonal anti-N-terminal htt N-18 (1:100). The filters were
incubated with the antibody at 4°C overnight in 5% nonfat dried milk. A
secondary goat anti-mouse (monoclonal antibodies) or goat anti-rabbit
(polyclonal antibodies) antibody (both 1:5000; Invitrogen, San Diego,
CA) was used followed by ECL detection (Amersham Biosciences, Ar-
lington Heights, IL).
Human samples. Fresh samples of the frontal cortex and striatum were
obtained at the time of the autopsy, and they were immediately frozen on
dry ice and stored at 80°C for biochemical studies. Control and HD
brain samples were processed following the same protocol as described
for mouse samples.
Quantification of immunoreactivity was performed by using a GS-710
Calibrated Imaging densitometer scanner controller by Quantity One PC
software from Bio-Rad (Hercules, CA). In all cases, the average intensity
value of the pixels in a background-selected region was calculated and
was subtracted from each pixel in the samples. The densitometry values
obtained in the linear range of detection with these antibodies were normal-
ized with respect to the values obtained with an anti--tubulin antibody to
correct for any deviation in loaded amounts of protein. Statistical analysis
was performed using one-way ANOVA followed by Bonferroni test.
Immunoelectron microscopy of purified aggregates
Single immunoelectron microscopy was performed after adsorption of
the samples to electron microscopy carbon-coated grids and incubation
with the first antibody (1:100) for 1 hr at room temperature. After exten-
sive washing, the grids were incubated with the secondary antibody (1:
40) conjugated with 10-nm-diameter gold particles. Finally, the samples
were stained with 2% uranyl acetate for 1 min. Transmission electron
microscopy was performed in a Jeol (Peabody, MA) model 1200EX elec-
tron microscope operated at 100 kV.
Double immunoelectron microscopy with the polyclonal antibody
CAG53b and the monoclonal antibody FK2 was developed as described
before for single immunoelectron microscopy but mixing both antibod-
ies (1:300 CAG53b and 1:500 FK2). After extensive washing, the grids
were incubated with secondary antibodies (anti-mouse conjugated with
10-nm-diameter gold particles and anti-rabbit conjugated with 5-nm-
diameter gold particles, both 1:40). The samples were processed as de-
scribed before for single-immunolabeling.
Atomic force microscopy of purified aggregates
A 5 l aliquot of the different fractions of the sucrose gradient was de-
posited onto freshly cleaved mica (Electron Microscopy Sciences, Fort
Washington, PA) and allowed to adsorb for 1 min. The sample was
washed with deionized and double-distilled water, dried with nitrogen
gas, and imaged in air with a commercial microscope (Nanotec Elec-
tronica, Madrid, Spain) operating in noncontact dynamic mode as pre-
viously described (Moreno-Herrero et al., 2001, 2004). Images were pro-
cessed using WSxM freeware. To enhance surface details, the Laplacian
operator was applied to the topographic image, thus generating the im-
ages in the inserts.
Immunofluorescence studies
After pelleting and washing, aliquots from different steps of Huntingtin
filament-enriched fraction preparation were deposited onto coverslips
pretreated with poly-L-lysine and maintained for 45 min to allow setting
and sticking to the substrate. After treated with NH4Cl 50 mM, glycine 1
M, 1% BSA, and 1% Triton X-100 in PBS buffer, the samples were incu-
bated with primary antibodies at the following dilutions: polyclonal anti-
huntingtin N-terminal CAG53b (1:5000) and monoclonal anti-poly-
ubiquitin conjugates (FK2) (1:10,000). Subsequently, samples were
washed with PBS buffer and incubated with secondary antibodies at the
following dilutions: goat anti-rabbit IgG labeled with Texas Red from
Molecular Probes (Eugene, OR) (1:400) and goat anti-mouse IgG labeled
with Oregon green 488 from Molecular Probes (1:200). Finally, samples
were washed with PBS and mounted following the standard procedures.
Controls were performed by following the same procedure but substitut-
ing the primary antibodies with preimmune serum (in the case of poly-
clonal primary antibodies) or with an unrelated monoclonal antibody, or
just omitting any primary antibody.
Colocalization of two markers was analyzed by taking successive Ore-
gon green 488 and Texas Red fluorescent images using an Axioskop 2
plus microscope and a CCD camera (Coolsnap FX color). Positive signal
was considered for the different antibodies if the mean intensity value
was140 on a 0 –255 scale with 0 white and 255 black. The cutoff
value of 140 was determined from visual analysis of immunolabeling and
by comparison with control (maximal level obtained with pre-absorbed
antibodies).
Flow cytometry
After incubation with blocking buffer (PBS, 1% BSA, and 1% FCS) for 20
min at 4°C, samples were incubated with primary antibodies at the fol-
lowing dilutions: polyclonal anti-huntingtin N-terminal CAG53b
(1:300) and monoclonal anti-poly-ubiquitin conjugates (FK2) (1:300)
for 20 min at 4°C. Subsequently, samples were washed with PBS buffer
and incubated with goat anti-rabbit IgG labeled with Alexa 488 and goat
anti-mouse IgG labeled with Alexa 647 for 20 min at 4°C. To check
staining specificity, controls were performed by following the same pro-
cedure but substituting the primary antibodies with PBS in presence of
1% BSA. Samples were analyzed on a flow cytometer FACsCalibur (BD
Biosciences, Erembodegem, Belgium) using CellQuest software (BD
Biosciences).
Thioflavine S fluorescence spectroscopy
The 20 –50 fraction of the purification procedure was incubated with PBS
containing 10 M thioflavine S (ThS) at room temperature for 15 min.
Fluorescence was then measured with an Aminco Bowman Series 2 Lu-
minescence Spectrometer (Thermo Spectronic) with an excitation filter
of 440 nm and an emission filter of 510 nm. Measurements were per-
formed at room temperature either in plain PBS media or in PBS supple-
mented with 10M ThS. Background fluorescence and light scattering of
the sample without ThS was subtracted.
Results
Isolation of mutant htt aggregates from the brain of
Tet/HD94 mice
Tet/HD94 mice develop neuropil and nuclear inclusions that can
be detected with antibodies raised against N-terminal htt and
against ubiquitin (Yamamoto et al., 2000; Martin-Aparicio et al.,
2001; Diaz-Hernandez et al., 2003) (Fig. 1A,B). Because exon 1
mutant htt expression in Tet/HD94 mice is driven by the
CamKII promoter, inclusions are abundant in the whole fore-
brain. Interestingly, similarly to what happens in humans (Di-
Figlia et al., 1997; Gutekunst et al., 1999), inclusions are more
abundant in cortex (Fig. 1A) than in striatum (Fig. 1B) of Tet/
HD94 mice. Also in good agreement with what has been described in
other HD mouse models (Davies et al., 1997; Yu et al., 2003) and in
humans (DiFiglia et al., 1997; Gutekunst et al., 1999), ultrastructural
analysis of Tet/HD94 brain sections immunostained with anti-N-
terminal htt or anti-ubiquitin antibodies revealed that inclusions are
composed of fibrillar structures (Fig. 1C,D).
For the biochemical isolation of aggregates, we thus excised
the entire forebrain of Tet/HD94 and control littermates and
subjected them to a procedure similar to the one used to isolate
the aberrant intraneuronal proteinaceous deposits from the brain
of Alzheimer’s disease (Greenberg and Davies, 1990) and Parkin-
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son’s disease patients (Pollanen et al., 1992). Essentially, tissue is
homogenized in a high salt buffer, followed by extraction with the
nonionic detergent Sarkosyl, and subsequent sucrose gradient
fractionation (see Materials and Methods) (Fig. 2A).
To verify that the subsequent steps of the procedure led to
progressive isolation of polyQ-containing aggregates, we took
advantage of previously published work. More precisely, it had
been shown that polyQ inclusions are SDS and Triton X-100-
resistant in cell transfection experiments (Kazantsev et al., 1999)
and that they can be monitored in cell transfection and in in vitro
assembly experiments as the material retained in a filter trap or in
the stacking gel of SDS-PAGE that is immunoreactive with anti-
N-terminal htt or anti-polyQ antibodies (Scherzinger et al., 1997,
1999). Therefore, during the optimization of the purification
procedure we were able to track the polyQ-containing aggregates
by Western blot as the material retained in the stacking gel and
that is recognized by N-terminal mutant htt (Fig. 2B), poly-
ubiquitin (Fig. 2C), or polyQ (1C2; data not shown) antibodies.
The subsequent enrichment in polyQ-containing aggregates was
made evident by Ponceau red or Coomasie blue staining of the
total protein content in the different steps of the purification
procedure (Fig. 2D) (data not shown). In parallel, we also ana-
lyzed the effect of the different steps of the purification procedure
on the number and size of N-terminal htt- and ubiquitin-
containing particles by double immunofluorescence in suspen-
sions of the different fractions and subsequent analysis either by
fluorescence microscopy on poly-lysine-coated coverslips or by
flow cytometry (see Fig. 5).
As it can be seen in Figure 2, B and C, total homogenates in
high salt buffer from Tet/HD94 forebrain contain N-terminal
htt-positive and ubiquitin-positive aggregated material that is
not present in the homogenates from control littermates. Re-
peated low field centrifugation to get rid of myelin sheets as well
as non-lysed membrane organelles and nuclei resulted in a solu-
ble fraction (S1 plus S2) containing most of the N-terminal htt-
containing and ubiquitin-containing aggregated material, but
lower total protein content (Fig. 2B–D). Extraction of the S1 plus
S2 fraction with the nonionic detergent Sarkosyl in the presence
of -mercaptho-ethanol, followed by high field centrifugation
resulted in a pellet fraction (P3) highly enriched in htt-containing
and ubiquitin-containing aggregated material (Fig. 2B–D). Fi-
nally, we were able to separate the aggregated material from the
little residual soluble protein present in P3 (Fig. 2A–D) by a
sucrose gradient centrifugation. After this, the htt-containing
Figure 1. Neuropil and nuclear inclusions in the cortex and striatum of Tet/HD94 mice:
immunohistochemical detection andultrastructural analysis.A, B, Immunohistochemistrywith
anti-N-terminal mutant htt (CAG53b) antibody revealed the presence of aggregates in the
cortex (A) and striatum (B) of Tet/HD94mice. Both nuclear (empty arrows) and neuropil (black
thin arrows) inclusions, aswell as dystrophic neurites (black solid arrows) canbedetected. Scale
bar, 20m. C, D, Ultrastructural transmission electron microscopy analysis of CAG53b stained
neuropil inclusion ( C) or dystrophic neurite (D) from the cortex of a Tet/HD94mouse. Inset in C
showsa3.5magnificationof the indicatedarea. Inset inD showsa2.5magnificationof the
indicated area. Scale bars, 500 nm.
Figure 2. Isolation of N-terminal htt-containing and ubiquitin-containing aggregates from
the brain of Tet/HD94 mice. A, Protocol for isolation of aggregates from the forebrain of Tet/
HD94 mice. B–D, The progressive enrichment in aggregated material in the different fractions
along the procedure is monitored by Western blot with anti-N-terminal mutant htt (CAG53b)
antibody (B) or anti-poly-ubiquitin antibody ( C). Arrows indicate the accumulation of aggre-
gatedmaterial in the stacking gel.D shows total protein content by Ponceau red staining of the
nitrocellulose membrane.
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and ubiquitin-containing aggregated material was retained in the
20 –30% sucrose interphase, whereas the residual soluble protein
was in the pellet and/or in the 50% sucrose phase. The gradient
was accordingly simplified to 10, 20, and 50% sucrose phases in
subsequent experiments, as shown in Figure 2A.
N-terminal huntingtin-containing and ubiquitin-containing
filaments are the high salt-resistant and detergent-resistant
component of Huntington’s disease inclusions
We next analyzed by immuno-EM, the morphology of the htt-
containing and ubiquitin-containing aggregated material present
in P3 and in the 20 –50% interphase. Immunogold labeling of the
P3 fractions revealed that the N-terminal htt (Fig. 3A–C) and
ubiquitin-containing (Fig. 3D,E) aggregates isolated from Tet/
HD94 mouse brain were filamentous structures similar to those
seen in the inclusions by ultrastructural analysis of Tet/HD94
brain tissue (Fig. 1C,D). Thus suggesting that, during the purifi-
cation procedure, spheroid inclusions disassemble into their con-
stituent filamentous material. In good agreement with the West-
ern blot data, no immunoreactive material was found in P3
fractions from control littermates (data not shown). The length
of the purified filaments varied considerably from 150 nm to1
m. They were essentially straight fibrils, especially those shorter
than 200 nm. However, longer ones showed multiple mild turns
(15–20°) without any apparent periodicity (Fig. 3A–E) and, oc-
casionally, they also showed more dramatic turns (up to 60 –70°)
(data not shown) (Fig. 4B,C). The width also varied considerably
from one filament to another, ranging from 15 to 40 nm. The
thinnest filaments (Fig. 3B,D) were quite uniform in width
(15–20 nm). Thicker ones, on the contrary, were less homoge-
neous, and they seemed to be composed of two or more aligned
thin filaments (Fig. 3C,E).
Because N-terminal htt-immunodecorated fibrils (Fig. 3A–C)
had similar morphologies to those decorated with anti-ubiquitin
antibodies (Fig. 3D,E), it was plausible that both molecules coex-
ist in the same filaments. To test this, we performed double-
labeling immuno-EM experiments with secondary antibodies
conjugated with gold particles of different sizes. As shown in
Figure 3F, 5 and 10 nm gold particles codecorate the same fila-
ments, thus demonstrating that N-terminal htt and ubiquitin
coexist in the same fibrils.
Immuno-EM experiments in the 20 –50% fraction revealed
that the N-terminal htt-containing and ubiquitin-containing
material consisted of the same type of filaments as described for
the P3 fraction but, in good agreement with what was shown in
Figure 3. Immunoelectronmicroscopy analysis of the aggregates isolated from the brain of
Tet/HD94mice. P3 (A–F) or 20–50%(G) fractions of the purificationprocedurewere subjected
to immunodecoration with anti-N-terminal mutant htt (CAG53b) antibody (A–C, G), or with
anti-poly-ubiquitin antibody (D, E) or with both antibodies ( F) and secondary antibodies con-
jugatedwith gold particles. Thin arrow in A indicates a thin filament like those shown at higher
magnification inB andD. Thick arrow inA indicates a thicker filament like those shownat higher
magnification in C and E. For the double immunodetection in F, CAG53b staining is detected
with a secondary antibody conjugatedwith 10 nmgold particles, and poly-ubiquitin staining is
detected with a secondary antibody conjugated with 5 nm gold particles. Inset in bottom right
corner of F shows a higher magnification for a better discrimination of 10 and 5 nm gold
particles.
Figure 4. AFM analysis of filaments purified from Tet/HD94 mice. P3 (A) and 20–50%
fractions (B, C) of the purification procedure were analyzed by AFM. C shows a higher magnifi-
cation of the filament depicted in B. To enhance the details of the structure, the Laplacian
operator was applied to the topographic images (inserts). A bead on a string morphology is
clearly visible from the data. In C are depicted the trajectories of the height measurements (1
and 2) shown in the bottom right quadrant.
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Figure 2D–F, virtually devoid of unlabeled contaminant material
(Fig. 3G) (data not shown).
Atomic force microscopy analysis of mutant N-terminal htt
filaments from Tet/HD94 mice
For a more precise analysis of the morphology of the aggregated
material purified from Tet/HD94 mouse brain, we performed
atomic force microscopy (AFM) studies on the P3 (Fig. 4A) and
20 –50% (Fig. 4B,C) fractions. In good agreement with the
immuno-EM and Western blot data, the 20 –50% samples show a
cleaner appearance and a higher density of filaments. Similar to
what has been described regarding the immuno-EM experi-
ments, individual filaments were straight with occasional turns
and were several hundred nanometer long. Interestingly, AFM
revealed that the filaments were not uniform in shape but pre-
sented a beads on a string morphology, thus resembling the in
vitro assembled filaments made of recombinant N-terminal mu-
tant huntingtin (Poirier et al., 2002), as well as the A and
-synuclein amyloid protofibrils (Dobson, 2003). AFM analysis
also allowed us to measure the height of these filaments. Because
Tet/HD94 filaments had a beads on a string morphology, their
maximal height of the Tet/HD94 filaments was, therefore, that of
the central part of the beads, which varied from 6 to 7.5 nm (Fig.
4C, measurement 1 as an example of a given bead, profile 2 to see
the variable height of the peaks). The minimal height, on the
opposite, was measured in the border between adjacent beads
and was5 nm (Fig. 4C, height profile 2). Regarding the filament
width, although this measurement is affected by the finite size of
the tip, we were able to estimate widths of 13 and 18 nm for the
areas of low and high height, respectively (Fig. 4C, measurement
1). As mentioned above, the morphology of the filaments is sim-
ilar to a succession of bead-shape features. The length of each of
these beads was quite variable. We found a bead length as small as
5 nm and a maximum length of 20 nm, with a mean value of 14
4 nm (Fig. 4C, height profile 2).
The size and number of spheroid inclusions decrease
progressively during the purification procedure
As mentioned above, during the optimization of the purification
procedure we analyzed the effect of the different steps on the
number and size of N-terminal htt-immunolabeled and
ubiquitin-immunolabeled particles by double immunofluores-
cence labeling in suspensions of the different fractions and sub-
sequent analysis either by fluorescence microscopy on poly-
lysine-coated coverslips or by flow cytometry (Fig. 5). In good
agreement with the immunohistochemistry data shown in Figure
1, A and B, after isotonic homogenization, N-terminal htt and
ubiquitin double-labeled particles corresponded to spheroids
with diameters ranging between 0.5 and 5 m (data not shown).
Interestingly, 95.2% of the N-terminal htt-labeled particles were
also ubiquitin-positive. We then analyzed the effect of homoge-
nizing the tissue in high salt buffer (0.8 or 1.2 M NaCl) in the
number and size of these particles. Flow cytometry analysis re-
vealed that the total number of N-terminal mutant htt-labeled
particles did not change significantly (Fig. 5A). However, the
percentage of particles larger than the reference 2.5-m-
diameter beads decreased significantly by the raise in salt concen-
tration to 0.8 or 1.2 M NaCl by 48 and 53%, respectively ( p 0.1)
(Fig. 5B).
To further explore the effect of high salt on those particles
2.5 m, we performed semiautomated counting of double-
labeled particles (Fig. 5C). By this analysis, a dramatic decrease in
the percentage of particles with diameters between 2 and 4m or
4 m was also observed. Interestingly, we found that 0.8 M
NaCl resulted in a 110% increase ( p 0.05) in the percentage of
particles between 1 and 2 m, and 180% ( p 0.05) increase in
those detected particles 1 m. Very similar results were ob-
tained with 1.2 M NaCl. Therefore, diminishing protein–protein
interactions by exposure to high salt buffer seems to be enough
for partial disassembling of the inclusions into their constituent
filaments (that cannot be detected by immunofluorescence based
techniques).
Interestingly, the decrease in the size of the inclusions caused
by high salt exposure is key for their separation from non-lysed
membrane organelles and myelin sheets by low field centrifuga-
tion. As shown in Figure 5D, if the purification procedure is
performed after homogenization in isotonic buffer, 100% of the
aggregated material goes to P2 instead of P3.
Next, we analyzed the effect of Sarkosyl and -mercapto-
ethanol (ME), either individually or combined, on the number
and size of the particles previously exposed to 0.8 M NaCl. As
shown in Figure 5F, Sarkosyl incubation by itself produced a
dramatic decrease in the number of particles, as revealed by flow
cytometry analysis. Similar results were obtained by semiauto-
mated counting of double-labeled particles. Interestingly, ME
by itself had no effect, but potentiated the effect of Sarkosyl in
decreasing both the number and size of double-labeled particles
(data not shown).
In summary, these data suggest that, along the biochemical
procedure, inclusions disassemble into smaller aggregated mate-
Figure 5. The size and number of spheroid inclusions decrease progressively during the
purification procedure. A, B, Flow cytometry analysis of the total number of CAG53b and
ubiquitin-positive aggregates after homogenization of Tet/HD94 forebrain tissue at different
NaCl concentrations (A) and percentage of these inclusions with diameter2.5 m (B). C,
Semiautomated counting of double-labeled particles according to their diameter. D, Compari-
son of the effect of homogenization of tissue in isotonic (0.15 M NaCl) or high salt (0.8 M NaCl)
buffer on thedistributionof thehuntingtin-containing aggregatedmaterial betweenP2andP3
fractions. E, Solubilization of monomeric exon 1mutant htt band (44 kDa) by subjecting the P3
fraction to boiling during 15 min in 10% SDS and 10%ME containing buffer (); when this
solubilization step was omitted (), all htt immunoreactivity remained in the stacking gel. F,
Flow cytometry analysis of the total number of CAG53b-positive and ubiquitin-positive aggre-
gates remainingwhenhigh salt homogenates (Control) are subjected to 1%Sarkosyl extraction
for 2 hr at room temperature (Sarkosyl). G, Thioflavine S fluorescence in the 20–50 fraction of
Tet/HD94 mice with respect to the same fraction of control mice. *p 0.05.
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rial that can be detected by immunobiochemical procedures but
not by optical microscopy. To confirm that the remaining aggre-
gated material detected by Western blot at the top of the gel
corresponds to aggregates made of monomeric exon 1 mutant
huntingtin, we subjected the P3 and 20 –50 fractions to extraction
with a solution containing 10% each of SDS and ME at 100°C
for 15 min, in a similar way to what has been done to solubilize
tau from purified paired helical filaments isolated from Alzhei-
mer’s disease brains (Iqbal et al., 1984). As shown in Figure 5E,
this resulted in detection of a 44 kDa N-terminal htt-
immunoreactive band that corresponds to the monomeric trans-
genic exon 1 mutant huntingtin produced by neurons of Tet/HD94
mice (Martin-Aparicio et al., 2001) together with a reduction in the
htt-immunoreactive material at the top of the gel.
Finally, because AFM analysis of P3 and 20 –50 fractions re-
vealed filaments with a beads on string morphology similar to
that found in amyloid fibrils made of A or -synuclein, we
decided to incubate the 20 –50 fraction with the amyloid-labeling
dye thioflavine S. As shown in Figure 5G, there is a remarkable
205.8 16.2% increase ( p 0.05) in thioflavine S fluorescence
in the 20 –50 fraction from Tet/HD94 mice with respect to the
same fraction from control mice, thus strongly suggesting that
the purified material corresponds, indeed, to amyloid aggregates.
Tet/HD94 filaments revert in vivo after silencing mutant
N-terminal htt transgene expression
We have previously reported that HD inclusions are dynamic
structures in vivo. More precisely, we showed that abolishing
transgene expression in symptomatic Tet/HD94 mice (by admin-
istering the tetracycline analog doxycycline in the drinking water)
leads to disappearance of the inclusions detected by immunohis-
tochemistry (Yamamoto et al., 2000), with proteasome activity
being involved in this phenomenon (Martin-Aparicio et al.,
2001). However, in view of the here reported observation that
along the biochemical procedure, inclusions disassemble into
smaller filamentous aggregated material that can be detected by
immunobiochemical procedures but not
by optical microscopy, we wondered if
these high salt-resistant and detergent-
resistant filaments persist after silencing of
mutant N-terminal htt transgene expres-
sion in Tet/HD94 mice.
To test this, we performed the above
described purification procedure in paral-
lel with forebrain tissue from untreated
Tet/HD94 mice, Tet/HD94 mice that were
given 2 mg/ml doxycycline in the drinking
water for 4 months (as in Yamamoto et al.,
2000), and untreated control littermates.
As shown in Figure 6A, silencing mutant
huntingtin expression in Tet/HD94 mice
by doxycycline treatment for 4 months re-
sulted in a dramatic decrease in aggregated
material immunodetected with anti-N-
terminal htt and anti-ubiquitin antibodies
(Fig. 6A, total homogenates), thus ruling
out that the decreased inclusion load seen
by immunohistochemistry was a conse-
quence of mere disassembling into their
constituent filamentous material. The ac-
tual load of filaments was also dramati-
cally decreased as a consequence of trans-
gene expression shutdown, as it can be
seen in the P3 and 20 –50 fractions of the biochemical purifica-
tion procedure (Fig. 6A). More precisely, the aggregated material
detected with anti-N-terminal mutant htt showed a 89.88 
14.9% decrease in the P3 fraction and a 93.75 12.30% decrease
in the 20 –50 fraction. Similarly, the aggregated material detected
with the anti-polyubiquitin antibody showed a 70.82  14.6%
decrease in the P3 fraction and a 90.74 15.85% decrease in the
20 –50 fraction. The decrease in the number of filaments after
mutant-htt transgene shutdown was also evident by
immuno-EM analysis of these two fractions (Fig. 6B–D). As
shown in Figure 6D, transgene shutdown results in a 75% de-
crease ( p 0.05) in the number of mutant htt-labeled filaments.
The remaining filaments in doxycycline-treated Tet/HD94 mice
seemed shorter than the average seen in untreated Tet/HD94
mice (Fig. 6C). However, when we quantified the number of gold
particles per decorated structure as an indirect indication of fila-
ment length, such decrease did not reach statistical significance
(data not shown).
Mutant htt-containing and ubiquitin-containing aggregated
material can be purified fromHD postmortem brains, and it
also corresponds to filaments
The antibodies used for immunohistochemical detection of in-
clusions in the brain of Tet/HD94 mice (anti-N-terminal mutant
htt and anti-polyubiquitin) also detect inclusions in the cortex of
human HD brains (Fig. 7A,B). We thus decided to subject corti-
cal samples from grade 4 HD brains to the same biochemical
purification procedure described for mouse tissue and moni-
tored the isolation of aggregated material with these antibodies.
The P3 fraction from HD brains, but not from control human
brain contained aggregated material that is immunoreactive with
N-terminal mutant htt antibody (Fig. 7C) and with ubiquitin
antibody (data not shown). Similar to what has been described
for mouse tissue; sucrose gradient centrifugation allowed further
Figure 6. N-terminal mutant htt-containing and polyubiquitin-containing filaments revert in vivo after silencing mutant
N-terminal htt expression in Tet/HD94mice. A, Western blot analysis of the N-terminalmutant htt-containing and polyubiquitin-
containing aggregatedmaterial during the different steps of the purification procedure from the forebrain of Tet/HD94 or control
littermates ( C) either treated () or untreated () with 5mg/ml doxycycline in the drinkingwater for the last 4months. Arrows
indicate the accumulation of aggregated material in the stacking gel. B—D, Immuno-EM analysis of the filaments isolated from
the forebrain of Tet/HD94 mice: without pharmacological treatment (B) or after 4 months of transgene expression shutdown by
the administration of 5 mg/ml doxycycline in the drinking water ( C). D shows a quantification of the total number of filaments
isolated from either treated () or untreated () Tet/HD94 mice. *p 0.05.
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purification of the mutant htt-containing
and ubiquitin-containing aggregated ma-
terial that is retained in the 20 –50% inter-
phase (Fig. 7C).
Immunoelectron microscopy analysis
with CAG53b antibody of the P3 fraction
again demonstrated that the immunore-
active aggregated material corresponded
to filamentous structures (Fig. 7D). As
shown in Figure 7E, the 20 –50 fraction
had less contaminant material and we
were able to decorate the purified filamen-
tous structures with two different anti-
bodies against N-terminal htt (N-18 and
CAG53b antibodies) (Fig. 7E, full image
and insert, respectively) and with anti-
polyubiquitin and anti-polyQ antibodies
(data not shown). The filaments from the
human HD samples were much shorter
that those previously shown from the
brain of the mouse model, with lengths
ranging from 100 up to 250 nm, and they
often showed mild turns, thus resulting in
a short bent filament morphology (Fig
7D–G). In comparison to the filaments
isolated from Tet/HD94 mice, AFM anal-
ysis (Fig 7F,G) revealed that human HD
filaments are shorter (as above described
in the immuno-EM analysis) and thicker
(the measured width was 40 4 nm). The
human HD filaments also presented a
beads on a string morphology similar to
that found in Tet/HD94 mice. As for the
mouse filaments, the height of the human
filaments varied between 5.5 and 7.5 nm
(Fig. 7F,G, height profiles 1 and 2). How-
ever, the length of each bead was larger
and more variable (between 27 and 44
nm) in the human filaments, with an av-
erage value of 38 9 nm.
Discussion
Here we report, for the first time, a proto-
col to isolate the aberrant proteinaceous
aggregates found in the brain of HD pa-
tients. This protocol, based on high salt
homogenization, nonionic detergent ex-
traction, and sucrose gradient, was opti-
mized in our conditional mouse model of
HD and revealed that the stable aggre-
gated material corresponds to mutant
huntingtin-containing and ubiquitin-
containing filaments. Furthermore, AFM
revealed that these filaments had a beads
on a string morphology very similar to the
one described for in vitro assembled fila-
ments made of recombinant mutant htt
and of other amyloidogenic proteins.
These fibrils, although very stable in vitro,
are susceptible to revert in vivo as here demonstrated by shutting
down transgene expression in the conditional mouse model.
These studies will also allow further conformational studies, en-
zymatic assays, and proteomic analysis that will be crucial to
clarify the contribution of aggregates to HD pathogenesis.
Previous reports of HD aggregate isolation were restricted to
transfected cells and were based on the use of GFP fusion forms of
Figure 7. Mutant htt-containing and polyubiquitin-containing aggregated material can be purified from HD postmortem
brains, and it also corresponds to filaments. A, B, Immunohistochemistry of cortical sections from a grade 4 HD brain with
anti-polyubiquitin (A) and anti N-terminal mutant htt (B) antibodies. Arrows indicate some of the many stained neuropil inclu-
sions. C, Western blot analysis of the mutant htt-containing and polyubiquitin-containing aggregated material present in the P3
fraction of the purification procedure and in its sucrose fractionation, from the cortex of either a control subject ( C) or froma grade
4 HD brain (HD). D, E, Immuno-EM analysis of the P3 (D) or 20–50% ( E) fractionswith two different anti-N-terminal htt antibod-
ies: CAG53b (D, E, inset) or N-18 (full image in E). F–G, AFM analysis of filaments isolated from the cortex of an HD brain with the
corresponding height profiles (1 and 2). Laplacian operator filtered images are shown as inserts in the topographic images.
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mutant exon 1 htt (to allow separation in a cell sorter) and/or
CsCl gradient fractionation (Scherzinger et al., 1999; Suhr et al.,
2001; Hazeki et al., 2002; Mitsui et al., 2002). Studies on trans-
fected cells very often do not reflect the situation in the tissue of
an HD patient mainly because of the massive overexpression
achieved by transfection. In contrast, in the mouse models, the
levels of toxic proteins are adjusted to a maximum compatible
with the normal development of the animals but leading to pro-
gression to a relevant phenotype during adult life. As an example,
transfection of mutant huntingtin into primary cultured neurons
results in cell death (Saudou et al., 1998), whereas primary neu-
ronal cultures from mouse models do not show decreased viabil-
ity (Martin-Aparicio et al., 2001). Accordingly, no loss of striatal
neurons is detected at early stages of phenotype progression in
mouse models, despite obvious striatal atrophy and/or motor
deficits (Hansson et al., 1999; Guidetti et al., 2001; Martin-
Aparicio et al., 2001) or in grade 0 HD postmortem brains (Von-
sattel et al., 1985). Similarly, proteasome enzymatic activity as-
says with small fluorogenic substrates in extracts from transfected
and transduced cells revealed decreased 20S proteasome activity
(Bence et al., 2001; Jana et al., 2001; Nishitoh et al., 2002),
whereas no inhibition was detected in extracts from adult mice
with overt phenotype and an extensive load of polyQ aggregates
(Diaz-Hernandez et al., 2003; Herna´ndez et al., 2004). For all
these reasons it was crucial to develop a method to isolate htt
aggregates from mouse models and eventually from HD post-
mortem brains.
The enrichment in N-terminal htt-positive and ubiquitin-
positive aggregated material in P3 and 20 –50 fractions despite the
progressive disruption of the particles detected by double immu-
nofluorescence suggests that, along the biochemical procedure,
inclusions disassemble into smaller aggregated material that can
be detected by immunobiochemical procedures but not by opti-
cal microscopy. Because the EM and AFM studies revealed that
this aggregated material corresponds to filaments similar to those
detected inside the intact inclusion by ultrastructural analysis of
brain sections, it is conceivable that along the purification proce-
dure, inclusions disassemble into their constituent filaments.
The beads on a string morphology of the filaments revealed by
AFM is in contrast with the morphology of other filament-like
structures found in other neurodegenerative diseases like the
paired helical filaments isolated from Alzheimer’s disease pa-
tients, which present a clear helical and ribbon-like morphology
(Pollanen et al., 1994; Moreno-Herrero et al., 2001, 2004). How-
ever, the beads on a string morphology of the here purified fila-
ments is identical to that reported after in vitro assembling of
recombinant exon 1 mutant htt (Poirier et al., 2002) and very
similar to those generated by other amyloidogenic proteins such
as A,-synuclein, and yeast (prion) Sup35 NM peptide (Harper
et al., 1999; Rochet et al., 2000). The in vitro generation of these
amyloid fibrillar deposits is characterized by sequential forma-
tion of globular assemblies (like the beads of the filaments) that
can associate linearly to form single protofibrils (like the here
reported individual 15–20 nm filaments). Finally, mature fiber
formation results from the lateral association of two or more
protofibrils (like the here reported 40 nm fibers). However, be-
cause the thin fibrils are larger in diameter than previously de-
scribed protofibrils, and these are usually thought of as being
transient intermediates (Dobson, 2003), the possibility also exists
that the thin fibrils could be mature fibrils and that the thicker
ones could result from longitudinal association of those thin
fibrils.
The filaments obtained after in vitro assembling of recombi-
nant mutant exon 1 htt (Poirier et al., 2002) and the here reported
after purification from the mouse model and from HD postmor-
tem brains have identical beads on a string morphology. They
also have the same height as measured by AFM. However, as
mentioned above, they differ in the diameter of the beads and
therefore, in the width resulting filaments (5 nm in the in vitro
assembled filaments, 13–18 nm in the filaments isolated from
Tet/HD94 mouse brains, and 36 – 44 nm in the filaments isolated
from postmortem HD brains). This increasing diameter of the
globular beads most likely reflects the increasing complexity of
the protein entities forming the aggregates. In the in vitro assem-
bled filaments, the only constituent protein is recombinant exon
1 htt with a 44 polyQ repeat. In the mouse model, the mutant htt
also corresponds to exon 1 htt (in this case, with a 94 polyQ
repeat), but it is not the only constituent because, at least, poly-
ubiquitin chains are also present in the filament. In the case of the
human filaments, the mutant htt molecules forming the fila-
ments are expected to be heterogeneous depending on their de-
gree of endoproteolytic cleavage from the full length form. Some
of the described endoproteolytic events lead to htt fragments very
similar to those generated from exon 1 constructs or transgenes
(Lunkes et al., 2002), whereas others result in significantly longer
forms of N-terminal mutant htt (Goldberg et al., 1996; Welling-
ton et al., 2000).
The N-terminal mutant htt in vitro assembled filaments have
been shown to be amyloid aggregates (Scherzinger et al., 1997,
1999; Poirier et al., 2002). In view of the morphological similarity
and the thioflavine S fluorescence data, it is reasonable to think
that filaments isolated from brain tissue are also amyloid aggre-
gates. More precisely, they resemble the protofibril stage of amy-
loid polymerization (Dobson, 2003). Interestingly, protofibrils
have been suggested to be more toxic than mature amyloid ag-
gregates (Conway et al., 2001; Klein et al., 2001). In such case,
accumulation of protofibrilar aggregates into mature inclusions
would represent a protective mechanism for the cell. We have
previously shown that inclusions are dynamic structures in vivo
and that they revert in parallel with behavioral phenotype im-
provement (Yamamoto et al., 2000; Martin-Aparicio et al., 2001).
If inclusion reversal were attributable simply to disassembling of
the inclusions into filaments, they should have been accompa-
nied by a detriment of the cellular physiology and behavioral
phenotype. In good agreement with the behavioral improve-
ment, here we found that the filaments, despite being very stable
in vitro, are susceptible to revert in vivo.
In summary, the here described work demonstrates that mu-
tant htt aggregated material can be isolated from the brain of HD
mouse models and from postmortem HD brains. The biochem-
ical and ultrastructural characterization of the isolated material
has revealed that it is formed by htt-containing and ubiquitin-
containing filamentous aggregates with a bead on string mor-
phology, and, more importantly, that these filamentous aggre-
gates are susceptible to revert in vivo, thus suggesting that any
associated toxicity is also likely to revert.
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